Your AI-Trained Oncology Knowledge Connection!
Loretta J. Nastoupil, MD, discusses the rationale for launching the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma, highlighting the background for investigating this treatment approach.
Loretta J. Nastoupil, MD, discusses the rationale for investigating the use of lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.
Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.
A discussion on which patients with relapsed/refractory follicular lymphoma are good candidates for CAR T-cell therapy.
Dr Marc S Hoffman reviews the currently available treatment options for relapsed/refractory follicular lymphoma.
Marc S. Hoffman, MD, explains how to select the appropriate CAR T-cell therapy for each patient, and the barriers patients with R/R LBCL face in receiving CAR T-cell therapy, despite its high efficacy rate.
Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.
Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.
Drs Loretta J. Nastoupil and Marc S Hoffman explain the available treatment options for relapsed/refractory diffuse large B-cell lymphoma and what to consider when selecting a therapy in the second-line setting.
Marc S. Hoffman, MD, provides an overview of recent updates in the treatment of relapsed/refractory diffuse large B-cell lymphoma.
